期刊文献+

采用DOE试验方法优化重组人干扰素α2a纯化工艺 被引量:2

Optimization of Purification Process for Recombinant Human Interferron-α2a by Design of Experiment
下载PDF
导出
摘要 目的采用DOE试验方法对重组人干扰素α2a纯化工艺参数进行优化,并寻找各参数的操作空间,为实际的产品生产提供指导。方法利用DOE中的中心符合表面设计(CCF)模型,设置两个响应值目标蛋白纯度和得率,对重组人干扰素α2a纯化工艺的疏水层析精纯进行优化并找出操作空间。选取两个工艺参数,即洗脱液B的(NH4)2SO4浓度(0.60M·L-1~0.70M·L-1)和洗脱液C的(NH4)2SO4浓度(0.30M·L-1~0.40M·L-1)。结果从模型的线性、正确性、有效性和重复性判断,所建立的模型拟合度高,可较为准确的预测实验结果。其中,洗脱液B的(NH4)2SO4浓度、洗脱液C的(NH4)2SO4浓度以及各自的平方对响应值有显著影响。同时,利用sweet spot找出关键层析步骤的操作空间。 OBJECTIVE Optimize the key parameters of recombinant human interferron-α2a purification process, find the operating space and provide guidance for the Pharmaceutical production. METHODS Finding the operating space of key purification process of recombinant human interferron-α2a by the central composite face-cen- tered design(CCF). For the hydrophobic interaction ,input two factors the concentration of ammonium sulfate in buffer B(0. 60M·L^-1 -0.70M·L^-1 )and the concentration of ammonium sulfate in buffer C(0.30M·L^-1 -0. 40M·L^-1 ), output two responses Purity and Yield. RESULTS From the regression coefficients, the predicted accuracy, the model validity and the reproducibility, we can draw the conclusion that the model is good fit, so it can be accu- rately predict the experimental results. For the hydrophobic interaction, the concentration of ammonium sulfate in buffer B, The concentration of ammonium sulfate in buffer C and their square items are the obvious significance. At the end, we got the operating space of the purification processes.
作者 苏诗蟠
出处 《海峡药学》 2017年第7期42-45,共4页 Strait Pharmaceutical Journal
关键词 DOE CCF 重组人干扰素Α2A 纯化工艺 DOE CCF Recombinant human interferron-a2a Purification process
  • 相关文献

参考文献4

二级参考文献33

  • 1刘伯宁.用于重组抗体生产的细胞大规模培养技术[J].中国生物工程杂志,2013,33(7):103-111. 被引量:13
  • 2周圆,金冬雁,曾庆,李玉英,迟捷,侯云德.重组人α2b型干扰素的纯化与鉴定[J].生物工程学报,1994,10(1):61-65. 被引量:6
  • 3郝学财,余晓斌,刘志钰,王蓓.响应面方法在优化微生物培养基中的应用[J].食品研究与开发,2006,27(1):38-41. 被引量:193
  • 4阎玉清,王晓沁,巫爱珍,孙玉昆.人干扰素α-2b生产工艺的研究[J].生物工程学报,1996,12(1):23-27. 被引量:9
  • 5F.奥斯伯 颜子颖(译).精编分子生物学实验指南[M].北京:科学出版社,1998.141.
  • 6Sacchis K, KantarjianH M,Brinen S,et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patient [J]. Cancer 1999, 15186 (12):2632-2641
  • 7奥斯伯 F,精编分子生物学实验指南,1998年
  • 8中国生物制品规程.一部,1996年
  • 9Shak S.Overview of the trastuzumab(Herceptin)anti-HER2monoclonal antibody clinical program in HER2-overexpression metastatic breast cancer[J].Semin Oncol,1999,26(Suppl12):71-77.
  • 10Hellstrm I,Goodman G,Pullman J,et al.Overexpressing of HER-2 in ovarian carcinomas[J].Cancer Res,2001,61(6):2420-2423.

共引文献7

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部